These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 15890242

  • 1. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test.
    Kakimoto M, Uetake H, Osanai T, Shirota Y, Takagi Y, Takeshita E, Toriya Y, Danenberg K, Danenberg PV, Sugihara K.
    Cancer Lett; 2005 Jun 01; 223(1):103-11. PubMed ID: 15890242
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.
    Kinoshita M, Kodera Y, Hibi K, Nakayama G, Inoue T, Ohashi N, Ito Y, Koike M, Fujiwara M, Nakao A.
    Anticancer Res; 2007 Jun 01; 27(2):851-6. PubMed ID: 17465211
    [Abstract] [Full Text] [Related]

  • 4. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
    Okumura K, Shiomi H, Mekata E, Kaizuka M, Endo Y, Kurumi Y, Tani T.
    Oncol Rep; 2006 Apr 01; 15(4):875-82. PubMed ID: 16525674
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
    Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV.
    Clin Cancer Res; 2000 Apr 01; 6(4):1322-7. PubMed ID: 10778957
    [Abstract] [Full Text] [Related]

  • 7. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C.
    Oncology; 2006 Apr 01; 70(5):366-77. PubMed ID: 17179731
    [Abstract] [Full Text] [Related]

  • 8. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
    Okumura K, Mekata E, Shiomi H, Naitoh H, Abe H, Endo Y, Kurumi Y, Tani T.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(4):587-94. PubMed ID: 17520254
    [Abstract] [Full Text] [Related]

  • 9. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma.
    Sasaki H, Fukai I, Kiriyama M, Kaji M, Yano M, Yamakawa Y, Fujii Y.
    Surg Today; 2003 Apr 01; 33(2):83-8. PubMed ID: 12616366
    [Abstract] [Full Text] [Related]

  • 10. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
    Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K, Hirayama R.
    Clin Cancer Res; 2003 Feb 01; 9(2):786-91. PubMed ID: 12576451
    [Abstract] [Full Text] [Related]

  • 11. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
    Nita ME, Tominaga O, Nagawa H, Tsuruo T, Muto T.
    Hepatogastroenterology; 1998 Feb 01; 45(24):2117-22. PubMed ID: 9951876
    [Abstract] [Full Text] [Related]

  • 12. [Expressions of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase in breast cancer and their correlations with prognosis].
    Li HX, Zh S, Zhang YH, Risberg B, Karlsson MG, Nesland JM.
    Zhonghua Zhong Liu Za Zhi; 2004 Nov 01; 26(11):669-72. PubMed ID: 15777505
    [Abstract] [Full Text] [Related]

  • 13. Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer.
    Inoue T, Hibi K, Nakayama G, Komatsu Y, Fukuoka T, Kodera Y, Ito K, Akiyama S, Nakao A.
    J Gastroenterol; 2005 Feb 01; 40(2):143-7. PubMed ID: 15770397
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
    Jakob C, Liersch T, Meyer W, Baretton GB, Schwabe W, Häusler P, Kulle B, Becker H, Aust DE.
    Am J Surg Pathol; 2006 Sep 01; 30(9):1169-74. PubMed ID: 16931962
    [Abstract] [Full Text] [Related]

  • 15. In vitro sensitivity to platinum-derived drugs is associated with expression of thymidylate synthase and dihydropyrimidine dehydrogenase in human lung cancer.
    Takizawa M, Kawakami K, Obata T, Matsumoto I, Ohta Y, Oda M, Sasaki T, Watanabe G.
    Oncol Rep; 2006 Jun 01; 15(6):1533-9. PubMed ID: 16685392
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H, Iinuma H, Watanabe T.
    Oncol Rep; 2008 Mar 01; 19(3):729-35. PubMed ID: 18288408
    [Abstract] [Full Text] [Related]

  • 17. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Kornmann M, Schwabe W, Sander S, Kron M, Sträter J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H, Häusler P, Ott K, Behnke D, Staib L, Beger HG, Link KH.
    Clin Cancer Res; 2003 Sep 15; 9(11):4116-24. PubMed ID: 14519634
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.